INTRODUCTION

Endoscopic
ultrasound-guided fine-needle aspiration (EUS-FNA) or EUS fine-needle biopsy (EUS-FNB) is a means of facilitating specimen procurement for microscopic analysis. Diagnostic samplings (cells or tissues) successfully obtained in this manner may greatly impact patient therapeutic management.
The guideline presented herein is based on our current understanding of the field. Various aspects of EUS-FNA (or EUS-FNB), ranging from preoperative preparation and clinical applications to major complications, are addressed. Related technologies with the potential to improve diagnostic accuracy are highlighted. We believe that this compilation may be helpful in clinical settings and the training of beginners. 
PATIENT PREPARATION
General considerations
•
Sedation during endoscopic ultrasound
• Topical pharyngeal anesthesia (e.g., lidocaine) is generally administered, and a sedative/hypnotic (e.g., midazolam) is appropriate to ease patient anxiety. Continuous monitoring of pulse, blood pressure, and oxygenation is also essential • Intravenous delivery of propofol by an anesthesiologist during endoscopy is considered safe and has become the preferred method for induction and maintenance of anesthesia [1] • General anesthesia (with endotracheal intubation) is not routinely used in this setting but may be required if propofol-induced respiratory failure should occur.
[2]
CLINICAL INDICATIONS
Submucosal tumors/subepithelial lesions
Submucosal tumors are neoplasms originating below digestive tract mucosa. Subepithelial lesion (SEL) is a term coined recently to denote growths beneath the epithelium. SELs may be neoplastic or nonneoplastic in nature, [3] ectopic pancreas being one example of nonneoplastic SEL. [4] EUS is the most accurate imaging technique for differentiating SELs and extramural distortions because information on location, size, echo pattern, and level of origin is conveyed. FNA may be performed jointly with EUS in hopes of establishing a pathologic diagnosis, a strategy proven accurate by some in pretherapeutic diagnosis of gastric SELs. [5] [6] [7] However, adequacy of sampling periodically falls short (17.7%) [6] or precludes warranted immunohistochemistry. [8] In a recent meta-analysis, EUS-guided needle sampling was shown safe but only moderately effective in diagnosing upper gastrointestinal (GI) SELs. The choice of needle for FNA, Tru-cut biopsy, or FNB (i.e., 19 gauge, 22 gauge, or 25 gauge) does not seem to alter overall diagnostic rates. [9] Furthermore, EUS-FNA is not always needed to diagnose SELs. Deep biopsy, also known as bite-on-bite or stacked forceps biopsy, is still considered the superior choice for pathologic evaluation. [10] Alternative methods available for tissue sampling include endoscopic mucosal resection, endoscopic submucosal dissection, and submucosal tunneling with endoscopic resection. [11] Before FNA is applied, patients' symptoms and comorbid conditions must be considered, as well as certain characteristics (size, location, and echo patterns) of lesions. It may be difficult to perform EUS-FNA in some instances of small-diameter SELs (~10 mm). To stabilize SELs during FNA, Yamabe et al. attached a cap device to the scope tip. [12] It has been acknowledged that EUS-FNA is particularly useful in circumstances where the pathologic diagnosis of SELs is critical but is not achievable through endoscopic forceps biopsy [6, 13] as follows: • A patient with history of malignant SELs (or other malignancy) to rule out possible metastasis • A patient with nonresectable malignant GI stromal tumor who may benefit from EUS-FNA before initiating tyrosine kinase inhibitor therapy.
Differential diagnosis of diffuse gastric wall thickening
Gastric wall thickening is detectable by EUS, showing which layers are involved and any structural loss. It may thus help identify the fundamental cause (i.e., infiltrating carcinoma, lymphoma, various metastases, eosinophilic gastroenteritis, Zollinger-Ellison syndrome, Menetrier's disease, tuberculosis, or amyloidosis). In this context, the false-negative rate for superficial biopsy is high. Deep biopsy, also known as bite-on-bite or stacked forceps biopsy, is a widely accepted alternate approach. There are few studies addressing the diagnosis of diffuse digestive wall thickening through EUS-FNA, but related data suggest a diagnostic yield of ~60%. [14] Hence, EUS-FNA is a viable option if bite-on-bite tissue sampling is nondiagnostic.
Solid pancreatic lesions
The accuracy of EUS-FNA in diagnosing pancreatic cancer is high, [15] [16] [17] [18] [19] [20] [21] making it the preferred method for pathologic diagnosis of pancreatic tumors. EUS-FNA generally provides adequate material for pathologic assessment. [22] [23] [24] According to a recent meta-analysis of pooled data, diagnostic sensitivity and specificity were 85% and 98%, respectively. [25] EUS-FNA is appropriate in the following circumstances:
• Suspected pancreatic cancer (first choice for pathologic diagnosis) • Preoperative assessments of patients with potentially resectable pancreatic neoplasms (whether needle tract is in surgically resected area or not) Ngamruengphong et al. recently reported outcomes of a retrospective population-based study examining the impact of preoperative EUS-FNA on overall and cancer-specific survival in patients with locoregional pancreatic cancer undergoing surgery with curative intent. In this instance, preoperative EUS-FNA bore no association with increased risk of mortality, suggesting that EUS-FNA is safe for diagnosing suspicious pancreatic lesions. [26] A smaller prior study likewise examined the effect of preoperative EUS-FNA on overall survival in patients with pancreatic neoplasms, finding no related adverse perioperative or long-term outcomes in cases with solid neoplasms after distal pancreatectomy [27] • Nonproductive EUS-FNA attempts Repeated EUS-FNA is a low-risk means of reaping substantial clinical benefits. [28] [29] [30] In clinical practice, repeat EUS-FNA is especially worthwhile if initial aspiration of a suspected tumor is nondiagnostic, but other signs of malignancy, such as vascular invasion or lymphadenopathy, are evident by EUS. In addition, if US or CT served initially for guidance, use of EUS-FNA on the next attempt may increase the diagnostic yield • Nonresectable pancreatic cancer (in examining suspected metastases during staging) • Distinguishing autoimmune pancreatitis (AIP) from pancreatic cancer Histologic diagnosis of AIP typically requires larger samples to evaluate architectural elements and perform immunostains. Only surgical or core biopsies are adequate for definitive diagnosis (specimens extracted through EUS-FNA providing too little tissue). [31] Nevertheless, there is recent evidence that EUS-FNA is safe and reliable in histologic documentation of AIP. [32] The diagnostic yield is not high, but surgery may be avoided in those patients who lack distinctive features of AIP [33] • Diagnosis of other solid pancreatic lesions (such as tuberculosis or abscess) if imaging evaluation is difficult.
Clinical reliability of endoscopic ultrasound-guided fine-needle aspiration in diagnosing pancreatic cystic lesions
Pancreatic cystic lesions (PCLs) comprise a diverse pathologic subset, with variable malignant potential. [34] Many PCLs (40%) are nonneoplastic (pseudocysts [PCs]; lymphoepithelial cyst; epidermoid, congenital, or retention cysts), but the majority are pancreatic cystic neoplasms, including intraductal papillary mucinous neoplasm, mucinous cystic neoplasm (MCN), serous cystic neoplasm, and cystic degeneration of solid tumors. The most important issues are ensuring appropriate (i.e., nonexcessive) patient treatment, thus limiting patient anxiety, and determining which patients may benefit from surgery. Despite the widespread availability of cross-sectional imaging and all pertinent technologic advances, PCLs are still diagnostically challenging. CT is a good-quality initial test to be used in accordance with clinical data although its diagnostic sensitivity is <70%. Magnetic resonance cholangiopancreatography may assist in ascertaining main pancreatic duct communication. [35] However, as a minimally invasive diagnostic tool, EUS-FNA provides investigators with cyst fluid for chemical and cytologic analyses. [36, 37] Cyst fluid biochemistry and tumor markers Cytopathology and analysis of conventional markers in cyst fluid, such as amylase, carcinoembryonic antigen (CEA), and cancer antigen (CA) 19-9, improve diagnostic capability. Of markers tested in cyst fluid, CEA (as opposed to CA 19-9, CA 72-4, or CA-125) is the most accurate index of pancreatic MCNs. In pancreatic cyst fluid, a CEA concentration of 192 ng/mL is the customary cut-point for differentiating mucinous from nonmucinous lesions. [38] Similarly, a fluid amylase level of <250 IU/L excludes the diagnosis of PC. At present, cytologic analysis of pancreatic cyst fluid confers no diagnostic benefit over radiologic findings alone. [39] Mediastinal lesions surrounding esophagus EUS has proved accurate in delineating middle and posterior mediastinal lesions surrounding the esophagus, and EUS-FNA is considered safe in this region. Although the role of EUS in the staging of lung cancer is still under evaluation, the diagnostic accuracy of FNA in mediastinal lesions is excellent. Researchers have confirmed a very high accuracy of FNA in mediastinal lymph nodes. [40, 41] Furthermore, in analyzing 153 EUS-FNA procedures targeting mediastinal lesions, Fritscher-Ravens et al. [42] reported high diagnostic sensitivity (92%), specificity (100%), and accuracy (95%). Unfortunately, EUS-FNA of cystic mediastinal lesions may culminate in severe infection that is nonpreventable through antibiotic prophylaxis. Because the results are unlikely to affect clinical decisions, caution is advised in such lesions.
If aspiration is done in more suitable regions, such as subcarinal area and pulmonary hilum, and lesion diameter is >2 cm, adequate representative samples may be anticipated for pathologic study. In contrast, sensitivity, accuracy, and sampling adequacy of EUS-FNA decline dramatically in lesions <1 cm across. The mediastinal organs maintain relatively stable positions that are seldom disturbed, so odds of serious procedural complications are minimal if sampling is properly done. Ultimately, EUS-FNA appears safe and effective for sampling of middle and posterior mediastinal lesions surrounding the esophagus.
The many important organs situated within mediastinum call for a skilled endoscopist to perform this procedure. In addition, baseline cardiorespiratory function should be evaluated beforehand, and blood oxygen saturation should be monitored during the procedure to avoid asphyxiation.
Esophageal cancer
EUS-FNA is recommended for the use in staging esophageal cancer. Its accuracy in confirming nodal and left hepatic metastases has been shown to surpass that of EUS and CT. [43] [44] [45] To evaluate esophageal cancer in the aftermath of adjuvant therapy, 18F-fluorodeoxyglucose positron emission tomography/CT remains the first choice. [46, 47] 
Gastric cancer
Although not a standard method of diagnosing gastric cancer, EUS-FNA is still a very important modality. FNA may help in diagnosing remote metastases, particularly if results may alter tumor staging and thereby the treatment received. [48, 49] 
Suspicious lymph nodes
The accuracy of FNA in lymph nodes is high. [43] If therapeutic strategy requires pathologic substantiation, and other biopsy methods are unavailable, EUS-FNA of a suspicious lymph node is recommended.
Rectal cancer
EUS-FNA is not routinely used for staging of rectal cancer. Preoperative staging is more often achieved through EUS alone, with no significant gain in accuracy by adding FNA. [50] EUS-FNA has been used to assess extramesenteric lymph nodes for early recurrence of rectal cancer. [51] Left adrenal masses EUS-FNA of the left adrenal gland is safe and may be useful in evaluation and staging of suspected malignancy. [52, 53] This approach is recommended if treatment strategies rely heavily on pathologic diagnosis. [54] Malignant biliary obstruction EUS-FNA is of great use in diagnosing malignant biliary obstruction, whether from cholangiocarcinoma or pancreatic cancer. [55, 56] In a prospective investigation by Weilert et al., EUS-FNA proved superior to endoscopic retrograde cholangiopancreatography (ERCP) in procuring tissue from presumptive sites, especially pancreatic masses. EUS-FNA should be performed before ERCP in all patients with suspected malignant biliary obstruction. [57, 58] 
TECHNIQUES TO INCREASE DIAGNOSTIC YIELD
Suction technique in solid lesions
Present opinions on the use of suction during fine-needle procedures vary. [59] [60] [61] Suction may contaminate the sample with blood, clouding cytologic interpretation. EUS-FNA done without suction or by slow-pull technique seems to fare better in terms accuracy and sensitivity of cytologic diagnoses, resulting in only slight blood contamination when aspirating solid lesions. [62] In histologic preparations, recent studies have confirmed that biopsy with (vs. without) suction is superior for tissue acquisition; [59] higher suction pressure seems to yield more tissue. [61, 63] Biopsy by wet suction technique will also enhance tissue procurement. [64] The quantity of tissue acquired through FNA of lymph nodes is usually good, but to reduce blood contamination, suction is not recommended. [65] Endoscopic ultrasound-guided fine-needle aspiration with or without stylet As indicated by prospective studies, neither the diagnostic yield in instances of malignancy nor the proportion of inadequate specimens differed in passes done with or without a stylet, regardless of specimen type (histologic or cytologic). [66] [67] [68] 
Needle diameter
The high-level evidence is still lacking in terms of needle choice (19 gauge, 22 gauge, or 25 gauge) for optimal diagnostic yield. Typically, 19 gauge is applied in interventional procedures, 22 gauge is routinely used to obtain histologic (tissue) specimens, and 25 gauge has gained in popularity for cytologic evaluations since the advent of rapid on-site evaluation (ROSE). Recently, a 25-gauge needle has been widely applied in aspirating solid pancreatic masses. Although a 19-gauge needle is more successful in aspirating mucinous cyst fluid, it is difficult to manipulate in transduodenal punctures.
Rapid on-site evaluation
In analyzing the performance of both EUS technologists and cytotechnologists, neither provided reliable assessments of FNA sampling adequacy (from pancreatic masses) by gross visual inspection of specimen-bearing slides. [69] False-positive assessments occurred in 30% of samples.
ROSE of EUS-FNA specimens is considered a highly accurate approach, comparing favorably with final cytologic outcomes. [70] Conducting ROSE during EUS-FNA of pancreatic masses reportedly correlated with improved adequacy and diagnostic yield, resulting in significantly fewer inadequate samples and fewer needle passes. [71] However, the current observational data on the impact of ROSE have been conflicting. In a recently published meta-analysis, comparing EUS-FNA with and without ROSE, no statistically significant difference in diagnostic yield or proportion of patients with adequate specimens was demonstrated. Diagnostic sensitivity and specificity were also comparable for both groups. [72] In most studies, the diagnostic yield through EUS-FNA and ROSE in combination may exceed 90%. However, similar results are achievable in high-volume centers, without ROSE, making further improvement difficult to envision. [73] A multiplicity of skills is required for successful results, so ROSE alone is not the overriding factor. In hospitals with diagnostic accuracy rates <90%, ROSE is nevertheless an important consideration. [74] Needle-pass estimates (without rapid on-site evaluation)
ROSE entails direct evaluation of smears produced at point of care in the endoscopy suite, which then aids in determining the number of passes in EUS-FNA needed for final diagnosis. However, ROSE is not an option in many centers. The endosonographer is not privy to immediate assessments and cannot guarantee that aspirates obtained are diagnostically adequate. Various studies have attempted to gauge needle passes appropriately, without benefit of ROSE. It appears that at least five to seven passes are required for pancreatic masses, three passes for lymph nodes, and only one pass for PCLs. [65, [75] [76] [77] 
COMPLICATIONS
Although few reports have focused on complications after EUS-FNA, published data have confirmed that related morbidity and mortality rates are relatively low, with most events qualifying as mild to moderate in severity. [78] In a systematic review conducted by Wang et al., EUS-FNA was found relatively safe, marked by a very low rate of complications (~1%) and a 0.98% (107/10,941) rate of procedure-related morbidity.
Of note, the complication rate for EUS-FNA of pancreatic cystic (vs. solid) lesions is higher by comparison. However, given the less-than-severe grades of complications and the clinical importance of this technique, the risk is acceptable. [79] Bleeding Severe bleeding is a rare complication of EUS-FNA, as a study based on nationwide administrative data in Japan has shown. [80] However, the incidence of severe bleeding in low-volume hospitals was shown to be 5-fold higher than rates in medium-and high-volume hospitals (P = 0.045), [80] supporting the notion put forth previously that complication frequencies in this setting reflect a learning curve. [81] Bleeding risk for endoscopic ultrasound-guided fine-needle aspiration in patients given anticoagulants The guidelines of major GI endoscopic societies list EUS-FNA as a high-risk procedure for bleeding. However, few studies have examined the risk of bleeding for EUS-FNA of solid organs in patients who continue antithrombotic treatment. One study by Inoue et al. cites a low incidence of bleeding related to EUS-FNA in patients receiving antithrombotic agents. Bleeding events were few, despite aspirin or cilostazol continuation. [82] Although EUS-FNA of solid lesions during clopidogrel use similarly may not place patients at high risk of bleeding, [83] discontinuation of low-molecular-weight heparins should be considered in advance of these procedures. [84] Tumor cell seeding
Concerns that tumor cells are seeded along needle tracks or within the peritoneum have limited the preoperative use of EUS-FNA in pancreatic cancer. [85] [86] [87] It appears that peritoneal carcinomatosis may occur with greater frequency in such patients who undergo percutaneous FNA. [88] Nevertheless, at least two investigations [88, 89] have yielded evidence to refute this argument, finding no increased risk of needle-tract seeding and supporting EUS-FNA as the diagnostic method of choice in patients with potentially resectable pancreatic cancer.
Infections
Clinical infectious complications are very rare after EUS-FNA of solid lesions, with incidences of 0%-0.6% in two large prospective series. [90, 91] Although EUS-FNA of PCLs has been linked to a higher rate of infection, [92] the risk is deemed acceptable as previously mentioned. Consideration should be given to the puncture of mediastinal cysts, [93] for which the rate of infection is much higher. Some infections due to mediastinal cyst aspiration are life-threatening, notably in bronchogenic cysts. [94, 95] Other rare conditions Mediastinitis after FNA has been described in a patient with sarcoidosis. [96] Bile peritonitis also reportedly developed after an inadvertent biliary puncture during EUS-FNA, [97] and hemothorax due to FNA of an SEL (in gastric fornix) has been documented. [98] Finally, acute ectopic pancreatitis is an unusual complication both induced and diagnosed through EUS-FNA and subsequently cured through surgery. [99] The guidelines above are based on a literature review and the consensus of endoscopic experts, hoping to be of clinical use and help train beginners. In this setting, however, clinical aspects are complex and evolving, requiring strategic modifications to meet individual needs. As technical developments and new research continue to surge, the future updates of these recommendations will follow.
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